These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32130725)

  • 1. Clinical significance of CD41-positive blasts in association with a monosomal karyotype in patients with myelodysplastic syndrome treated with azacitidine.
    Ogata K; Sei K; Kawahara N; Yamamoto Y
    Br J Haematol; 2020 May; 189(4):e144-e147. PubMed ID: 32130725
    [No Abstract]   [Full Text] [Related]  

  • 2. Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine.
    Matsuoka A; Tanibuchi M; Yamazaki I; Taoka T
    Int J Hematol; 2022 Jun; 115(6):852-859. PubMed ID: 35275354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)].
    Takahashi Y; Kimura S; Okano M
    Nihon Yakurigaku Zasshi; 2012 Nov; 140(5):235-43. PubMed ID: 23138323
    [No Abstract]   [Full Text] [Related]  

  • 4. Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.
    Cluzeau T; Mounier N; Karsenti JM; Richez V; Legros L; Gastaud L; Garnier G; Re D; Montagne N; Gutnecht J; Gabriel Fuzibet J; Auberger P; Raynaud S; Cassuto JP
    Am J Hematol; 2013 Sep; 88(9):780-3. PubMed ID: 23757315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
    Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
    [No Abstract]   [Full Text] [Related]  

  • 6. Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes.
    Kim IH; Youn JH; Shin SH; Yahng SA; Lee SE; Kwon JC; Lee DG; Park KS; Choi MH; Jung SE; Kim YJ
    Leuk Res; 2012 Jul; 36(7):e146-8. PubMed ID: 22483068
    [No Abstract]   [Full Text] [Related]  

  • 7. Azacitidine and the beginnings of therapeutic epigenetic modulation.
    O'Dwyer K; Maslak P
    Expert Opin Pharmacother; 2008 Aug; 9(11):1981-6. PubMed ID: 18627335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.
    Itzykson R; Thépot S; Quesnel B; Dreyfus F; Beyne-Rauzy O; Turlure P; Vey N; Recher C; Dartigeas C; Legros L; Delaunay J; Salanoubat C; Visanica S; Stamatoullas A; Isnard F; Marfaing-Koka A; de Botton S; Chelghoum Y; Taksin AL; Plantier I; Ame S; Boehrer S; Gardin C; Beach CL; Adès L; Fenaux P;
    Blood; 2011 Jan; 117(2):403-11. PubMed ID: 20940414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.
    Liapis K; Papadopoulos V; Vrachiolias G; Galanopoulos AG; Papoutselis M; Papageorgiou SG; Diamantopoulos PT; Pappa V; Viniou NA; Kourakli A; Τsokanas D; Vassilakopoulos TP; Hatzimichael E; Bouronikou E; Ximeri M; Pontikoglou C; Megalakaki A; Zikos P; Panayiotidis P; Dimou M; Karakatsanis S; Papaioannou M; Vardi A; Kontopidou F; Harchalakis N; Adamopoulos I; Symeonidis A; Kotsianidis I
    Blood Cancer J; 2021 Feb; 11(2):30. PubMed ID: 33574231
    [No Abstract]   [Full Text] [Related]  

  • 11. Azacitidine.
    Issa JP; Kantarjian HM; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Apr; 4(4):275-6. PubMed ID: 15861567
    [No Abstract]   [Full Text] [Related]  

  • 12. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine.
    Kamiya T; Nakazato T
    Med Oncol; 2019 Jan; 36(3):25. PubMed ID: 30706221
    [No Abstract]   [Full Text] [Related]  

  • 13. Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders.
    Tendas A; Lissia MF; Piccioni D; Tirimbelli L; Scaramucci L; Giovannini M; Dentamaro T; Perrotti A; de Fabritiis P; Niscola P
    Support Care Cancer; 2015 Feb; 23(2):303-5. PubMed ID: 25370894
    [No Abstract]   [Full Text] [Related]  

  • 14. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry.
    Comont T; Heiblig M; Rivière E; Terriou L; Rossignol J; Bouscary D; Rieu V; Le Guenno G; Mathian A; Aouba A; Vinit J; Dion J; Kosmider O; Terrier B; Georgin-Lavialle S; Fenaux P; Mekinian A;
    Br J Haematol; 2022 Feb; 196(4):969-974. PubMed ID: 34651299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The clinical research of treatment by decitabine moderate or high-risk myelodysplastic syndrome patients].
    Shao XR; Liang H; Guan XJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):789-91. PubMed ID: 22339920
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes.
    Chou WC; Yeh SP; Hsiao LT; Lin SF; Chen YC; Chen TY; Laille E; Galettis A; Dong Q; Songer S; Beach CL
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e430-e439. PubMed ID: 28124500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there an association between 5-azacitidine and ototoxicity?
    Malik A; Misbah S; Spaccavento C; Yudelman I
    J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015
    [No Abstract]   [Full Text] [Related]  

  • 18. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
    Gangatharan SA; Carney DA; Campbell LJ; Prince HM; Kenealy MK; Seymour JF
    Eur J Haematol; 2011 Aug; 87(2):186-8. PubMed ID: 21623918
    [No Abstract]   [Full Text] [Related]  

  • 19. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
    Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
    Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.
    Breccia M; Cannella L; Santopietro M; Loglisci G; Federico V; Salaroli A; Nanni M; Mancini M; Alimena G
    Leukemia; 2011 Apr; 25(4):736-7. PubMed ID: 21293489
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.